VIA ELECTRONIC MAIL (AGO.highcostprescriptiondrugs@vermont.gov)

May 7, 2021

To the Office of The Attorney General of Vermont

From: SK Life Science, Inc.

RE: 30-Day Notice of New Prescription Drug Pursuant to 18 V.S.A §4637(c)

On May 4, 2021, SK Life Science, Inc. (SKLSI) notified the Office of the Attorney General of Vermont of a new package of prescription drug XCopri® pursuant to 18 V.S.A §4637(b). SKLSI hereby notifies the Attorney General of Vermont of the following additional information, pursuant to 18 V.S.A §4637(c):

Name of Prescription Drug	NDC	Date of Commercial Availability	WAC (as of date of commercial availability)
XCOPRI® Tablets 100mg(28)+150mg(28)	71699010456	5/3/2021	$1,029.33

Description of the marketing and pricing plans used in the launch of the new drug in the United States and internationally
While specific marketing and pricing plans are not available in the public domain, generally, marketing activities that support the launch of a new medicine are designed to give healthcare providers and appropriate patients information about the new medicine, its approved indication(s), efficacy and safety data in accordance with the FDA approved label, this can be done through in-person promotion as well as digital and print advertising. When determining pricing of our medicines, we consider factors such as: how well the medicine works, particularly in comparison to other available treatments; the costs associated with discovering new medicines; and carefully consider how we can ensure that our medicine is available to people who need it. SK Life Science, Inc. does not market XCOPRI outside the US.

461 From Road 5th Floor, Paramus, New Jersey 07652 U.S.A. Tel) 201-421-3800 Fax)201-421-3838
sklifescienceinc.com

The estimated volume of patients who may be prescribed the drug
While SKLSI's estimated volume of patients who may be prescribed XCOPRI is not available in the public domain, XCOPRI is approved specifically for the treatment of adult patients with partial-onset seizures. The total number of partial-onset seizure patients in the US with this condition is estimated at 1.8 million.

Whether the drug was granted breakthrough therapy designation or priority review by the FDA prior to final approval
XCOPRI was not granted breakthrough therapy designation or priority review by the FDA prior to final approval.

The date and price of acquisition if the drug was not developed by the manufacturer
XCOPRI was not the result of an acquisition.

461 From Road 5th Floor, Paramus, New Jersey 07652 U.S.A. Tel) 201-421-3800 Fax)201-421-3838
sklifescienceinc.com